S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
2 Stocks to Benefit from the Aging Population
3 Warren Buffett Stocks that are Moving into the Buy Zone
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
3 Stocks That Really, Really Need the Defense Bill to Pass
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
2 Stocks to Benefit from the Aging Population
3 Warren Buffett Stocks that are Moving into the Buy Zone
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
3 Stocks That Really, Really Need the Defense Bill to Pass
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
2 Stocks to Benefit from the Aging Population
3 Warren Buffett Stocks that are Moving into the Buy Zone
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
3 Stocks That Really, Really Need the Defense Bill to Pass
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
2 Stocks to Benefit from the Aging Population
3 Warren Buffett Stocks that are Moving into the Buy Zone
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
3 Stocks That Really, Really Need the Defense Bill to Pass
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Hanes Worth More than the Sum of Its Parts?
NYSE:CANF

Can-Fite BioPharma (CANF) Stock Forecast, Price & News

$2.59
+0.10 (+4.02%)
(As of 09/26/2023 ET)
Compare
Today's Range
$2.48
$2.62
50-Day Range
$2.49
$3.12
52-Week Range
$1.52
$9.00
Volume
3,038 shs
Average Volume
48,287 shs
Market Capitalization
$9.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.00

CANF stock logo

About Can-Fite BioPharma (NYSE:CANF) Stock

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

CANF Price History

CANF Stock News Headlines

WARNING: Mandatory U.S. Dollar Recall is Weeks Away
If you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.
A 73-Year-Old Market Signal With 95% Accuracy Just Flashed
This signal has flashed just 24 times in the past 73 years – and it has signaled the exact moment to move your money with 95% accuracy. Now, it's flashing again. Discover where here.
Pre-market Movers: GFAI, SONO, KLXE, CDNA, DMRC…
CAN-FITE BIOPHARMA LTD ADR
See More Headlines
Receive CANF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Can-Fite BioPharma and its competitors with MarketBeat's FREE daily newsletter.

CANF Company Calendar

Last Earnings
8/31/2023
Today
9/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
8
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$23.00
High Stock Price Forecast
$34.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+788.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-10,170,000.00
Net Margins
-1,231.78%
Pretax Margin
-1,255.93%

Debt

Sales & Book Value

Annual Sales
$810,000.00
Book Value
$1.33 per share

Miscellaneous

Free Float
3,512,000
Market Cap
$9.17 million
Optionable
Not Optionable
Beta
1.30
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Pnina Fishman Ph.D. (Age 75)
    Founder, Chief Scientific Officer & Exec. Chairman
    Comp: $644k
  • Mr. Motti Farbstein (Age 59)
    CEO & Chief Operating and Financial Officer
    Comp: $414k
  • Dr. Sari Fishman Ph.D. (Age 51)
    VP of Bus. Devel.
    Comp: $325k
  • Dr. Ilan Cohn Ph.D. (Age 69)
    Co-Founder & Director
  • Dr. Stephen A. Harrison FACP
    M.D., Member of Clinical Advisory Board & Consulting Chief Medical Officer













CANF Stock - Frequently Asked Questions

Should I buy or sell Can-Fite BioPharma stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Can-Fite BioPharma in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CANF shares.
View CANF analyst ratings
or view top-rated stocks.

What is Can-Fite BioPharma's stock price forecast for 2023?

2 Wall Street research analysts have issued 12 month price objectives for Can-Fite BioPharma's stock. Their CANF share price forecasts range from $12.00 to $34.00. On average, they predict the company's share price to reach $23.00 in the next year. This suggests a possible upside of 788.0% from the stock's current price.
View analysts price targets for CANF
or view top-rated stocks among Wall Street analysts.

How have CANF shares performed in 2023?

Can-Fite BioPharma's stock was trading at $0.6130 on January 1st, 2023. Since then, CANF shares have increased by 322.5% and is now trading at $2.59.
View the best growth stocks for 2023 here
.

How were Can-Fite BioPharma's earnings last quarter?

Can-Fite BioPharma Ltd. (NYSE:CANF) posted its quarterly earnings results on Thursday, August, 31st. The company reported ($0.40) EPS for the quarter, beating analysts' consensus estimates of ($0.54) by $0.14. The company had revenue of $0.20 million for the quarter, compared to analysts' expectations of $0.20 million. Can-Fite BioPharma had a negative net margin of 1,231.78% and a negative trailing twelve-month return on equity of 143.29%.

When did Can-Fite BioPharma's stock split?

Can-Fite BioPharma shares reverse split before market open on Monday, January 9th 2023. The 1-10 reverse split was announced on Monday, January 9th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Can-Fite BioPharma's stock symbol?

Can-Fite BioPharma trades on the New York Stock Exchange (NYSE) under the ticker symbol "CANF."

How do I buy shares of Can-Fite BioPharma?

Shares of CANF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Can-Fite BioPharma's stock price today?

One share of CANF stock can currently be purchased for approximately $2.59.

How much money does Can-Fite BioPharma make?

Can-Fite BioPharma (NYSE:CANF) has a market capitalization of $9.17 million and generates $810,000.00 in revenue each year. The company earns $-10,170,000.00 in net income (profit) each year or ($3.06) on an earnings per share basis.

How can I contact Can-Fite BioPharma?

Can-Fite BioPharma's mailing address is 10 Bareket Street, Kiryat Matalon PO Box 7537, Petah Tikva 4951778, Israel. The official website for the company is www.canfite.com. The company can be reached via phone at 972-3-924-1114, via email at info@canfite.co.il, or via fax at 972-3924-9378.

This page (NYSE:CANF) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -